The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer

e16059 Background: Prostate cancer truly is an age-associated disease, approximately half of prostate cancer patients in the Netherlands are aged 70 years or older at the time of diagnosis. However, age above 70 years has been an exclusion criterion in many clinical trials. Hence the knowledge about chemotherapy tolerance and toxicity in patients aged 70 years and above is limited. In this study we evaluated the influence of age on docetaxel chemotherapy in elderly (≥70yrs) castration resistant prostate cancer (CRPC) patients. Methods: Prostate cancer truly is an age-associated disease, approximately half of prostate cancer patients in the Netherlands are aged 70 years or older at the time of diagnosis. However, age above 70 years has been an exclusion criterion in many clinical trials. Hence the knowledge about chemotherapy tolerance and toxicity in patients aged 70 years and above is limited. In this study we evaluated the influence of age on docetaxel chemotherapy in elderly (≥70yrs) castration resistant prostate cancer (CRPC) patients. Results: We analyzed 568 patients (median age 68.1yrs, range 46-89yrs, 44.5% aged ≥70yrs). There was no relation between dosage and age (p=0.60). We found no significant differences between the number of dose reductions, TTP, overall survival, chemotherapy tolerance and toxicity up to the age of 80 years. However, when compared to younger men, men aged 80 years or above more frequently experienced grade 3/4 toxicity, were five times less likely to complete the first three treatment cycles at the intended dose (OR5.34, p=0.0052) and showed decreased overall survival (15.3mos versus 24.5mos in <80yrs group, p=0.020). Conclusions: In mCRPC, and possibly other cancer patients, up to the age of 80 years docetaxel chemotherapy is well tolerated with toxicity levels, tolerance and TTP comparable to that of younger patients. However, for chemotherapeutic treatment of patients aged 80 years and above an individual assessment should be made.

Download Full-text

Oncological outcomes of metastatic castration resistant prostate cancer (mCRPC) treated with different therapies sequences after completion of docetaxel: a retrospective study in Songklanagarind Hospital

Insight Urology ◽

10.52786/isu.a.35 ◽

2021 ◽

Vol 42 (2) ◽

pp. 131-137

Author(s):

Isaris Chaokhamin ◽

◽

Worapat Attawettayanon ◽

Virote Chalieopanyarwong ◽

Monthira Tanthanuch ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Proportional Hazards ◽

Multivariable Analysis ◽

Abiraterone Acetate ◽

Cox Proportional Hazards ◽

Castration Resistant Prostate Cancer ◽

Oncological Outcomes ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Objective: Many treatment options of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy have proved efficacious in clinical trials but, to date, knowledge regarding oncological outcomes is limited. Materials and Methods: We assessed the oncological outcome of 4 drugs (abi- raterone acetate, cabazetaxel, enzalutamide and ketoconazole) in a normal clinical setting in a university-based hospital. Our cohort consisted of 69 patients with post-docetaxel mCRPC. The primary endpoint was overall survival (OS). The secondary endpoint was predicted factor associated overall survival with all sec- ond-line mCRPC treatment outcomes according to the Cox proportional hazards regression model. Results: This cohort consisted of 69 patients with progressive mCRPC after docetaxel chemotherapy. Median overall survival following treatment with abiraterone acetate and ketoconazole was 25.92 and 9.59 months respectively (p < 0.05). Overall survival rates at 1-year following abiraterone acetate, cabazetaxel, enzalutamide and ketoconazole therapy were 76.3%, 83.3%, 100% and 41.9%, respectively. Multivariable analysis found that abiraterone acetate, cabazitaxel and enzalutamide significantly improved survival in comparison to ketoconazole (p < 0.001). Conclusion: Analysis of overall survival following second-line treatment of mCRPC post docetaxel in our study statistically significantly confirmed that abiraterone acetate, cabazitaxel and enzalutamide improve overall survival in comparison to ketoconazole. The study also found that enzalutamide treatment resulted in better outcomes in comparison to the other drugs.

Download Full-text

The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2014.04.008 ◽

2015 ◽

Vol 13 (1) ◽

pp. 32-38 ◽

Cited By ~ 9

Author(s):

Jong Chul Park ◽

Caroline F. Pratz ◽

Anteneh Tesfaye ◽

Robert A. Brodsky ◽

Emmanuel S. Antonarakis

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Therapeutic Anticoagulation ◽

Docetaxel Chemotherapy

Download Full-text

Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e16530 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e16530-e16530

Author(s):

Masahito Watanabe ◽

Kent Kanao ◽

Hiroyuki Muramatsu ◽

Shingo Morinaga ◽

Keishi Kajikawa ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Progression Free Survival ◽

Castration Resistant Prostate Cancer ◽

Free Survival ◽

Chemical Castration ◽

Castration Resistant ◽

Lh Rh ◽

The Impact ◽

Docetaxel Chemotherapy

e16530 Background: Docetaxel is the standard treatment for castration-resistant prostate cancer (CRPC). However, the role of chemical/surgical castration during docetaxel chemotherapy is unclear. The purpose of this study was to analyze the impact of castration during docetaxel chemotherapy. Methods: Data from 43 patients diagnosed with CRPC and treated at our institute with docetaxel chemotherapy, from January 2007 to September 2016, were analyzed retrospectively. They were divided into two groups according to the continuation of chemical castration during docetaxel chemotherapy: a continuation group and a discontinued group. Patients’ background data (age and serum prostate-specific antigen [PSA] level), PSA decline, progression-free survival, and overall survival were compared between the two groups. Results: The continuation group included 19 patients, and the discontinued group included 24 patients. Castration included surgical castration (15.8%), use of a luteinizing hormone-releasing hormone (LH-RH) agonist (68.4%), and use of an LH-RH antagonist (15.8%). There were no significant differences in patient age (73.5 years vs. 73.5 years; p = 0.878) and baseline serum PSA levels (14.25 ng/ml vs. 31.1 ng/ml, p = 0.745) between the two groups at the start of chemotherapy. PSA declines of ≥50% were observed in 7/14 patients and in 9/20 patients, respectively. There were no significant differences between the two groups with respect to the median progression-free survival (5.7 months vs. 9.9 months, p = 0.406) and overall survival. (52.1 months vs. 44.1 months, p = 0.776). Conclusions: Continuing chemical/surgical castration during docetaxel chemotherapy did not affect progression and prognosis of CRPC. Our results might suggest that chemical castration is not necessary during docetaxel chemotherapy.

Download Full-text

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Download Full-text

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Therapeutic Advances in Medical Oncology ◽

10.1177/1758835920978134 ◽

2020 ◽

Vol 12 ◽

pp. 175883592097813

Author(s):

Pernelle Lavaud ◽

Clément Dumont ◽

Constance Thibault ◽

Laurence Albiges ◽

Giulia Baciarello ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Androgen Receptor ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Next Generation ◽

Castration Resistant Prostate Cancer ◽

Free Survival ◽

Castration Resistant ◽

Recent Advances

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Download Full-text